16 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembrane anion transporters (TAT-CF)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2018,
This project will develop an innovative therapeutic approach for the treatment of Cystic Fibrosis (CF). This condition originates from the defective function of the CFTR protein, a chloride and bicarbonate permeable transmembrane channel. This project will evaluate small molecules capable of facilitating the transmembrane transport of anions such as chloride and bicarbonate and will thus enable CF ...
Voir le projet
8
Participants partenaires
TERMINÉ
PanCare Studies in Fertility and Ototoxicity to Improve Quality of Life after Cancer during Childhood, Adolescence and Young Adulthood (PANCARELIFE)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,
Survival rates after childhood cancer now reach nearly 80% in developed European countries as a result of more effective therapies and better supportive care, leading to a steady increase in the number of survivors in the population. However, the treatments that have improved survival are harsh and cause serious side-effects that can greatly impact survivors’ quality of life in the long term. The ...
Voir le projet
19
Participants partenaires
TERMINÉ
Development and Epilepsy - Strategies for Innovative Research to improve diagnosis, prevention and treatment in children with difficult to treat Epilepsy (DESIRE)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,
DESIRE will focus on epileptogenic developmental disorders EDD, i.e. early onset epilepsies whose origin is closely related to developmental brain processes. A major cause of EDD are malformations of cortical development (MCD), either macroscopic or subtle. EDD are often manifested as epileptic encephalopathies (EE), i.e. conditions in which epileptic activity itself may contribute to severe cogni ...
Voir le projet
29
Participants partenaires
TERMINÉ
New approach to treatment of the blinding disease Retinopathy of Prematurity (ROP) (PREVENTROP)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,
"The overall objective is to develop a novel preventative intervention for the blinding disease retinopathy of prematurity (ROP) and other complications of prematurity. The PREVENTROP consortium proposes to conduct preclinical studies (pharmacological, pharmacodynamics, pharmacokinetics and toxicological) in models and/or clinical studies (including phase III clinical trial) of an EU designated o ...
Voir le projet
10
Participants partenaires
TERMINÉ
GAbapentin in Paediatric Pain (GAPP)
Date du début: 1 juil. 2013, Date de fin: 30 juin 2017,
Chronic pain is estimated to affect 15-20% of children with varying disabilities. Due to the paucity of clinical information and appropriate medicinal products, in clinical practice paediatric patients are often under-treated causing profound impact on their QoL.To date, opioids, non-steroid anti-inflammatory drugs (NSAIDs), antidepressants and anticonvulsants are used to treat pain, but only few ...
Voir le projet
16
Participants partenaires
TERMINÉ
Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk (ABIRISK)
Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,
The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recru ...
Voir le projet
39
Participants partenaires
TERMINÉ
PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies (PanCareSurFup)
Date du début: 1 févr. 2011, Date de fin: 31 janv. 2017,
Over the last 40 years, treatment for childhood and adolescent cancer has improved greatly; 5- year survival after childhood cancer is now 80% in developed countries. Approximately 1 individual in 750 of young adults is now a childhood cancer survivor. Epidemiologic data on the number of European childhood cancer long-term survivors are not available, but estimates suggest a number between 300,000 ...
Voir le projet
18
Participants partenaires
TERMINÉ
EUropean TRanslational training for Autoimmunity & Immune manipulation Network (EUTRAIN)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,
Immune-mediated inflammatory diseases (IMID) are important health challenges in Europe and beyond, afflicting an estimated 5-8% of the total population. IMID with an onset during childhood such as Juvenile Idiopathic Arthritis (JIA) cause particular concern as pediatric patients form an especially vulnerable group. Currently there is no safe and cost-effective cure for JIA and related juvenile IMI ...
Voir le projet
11
Participants partenaires
TERMINÉ
EUROPEAN NETWORK for CANCER research in CHILDREN and ADOLESCENTS (ENCCA)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,
"ENCCA aims to establish a durable, European Virtual Institute clinical and translational research in childhood and adolescent cancers that will define and implement an integrated research strategy and will facilitate the necessary investigator-driven clinical trials to introduce the new generation of biologically targeted drugs into standard of care for children and adolescents with cancer. This ...
Voir le projet
34
Participants partenaires
TERMINÉ
Epilepsy Pharmacogenomics: delivering biomarkers for clinical use (EpiPGX)
Date du début: 1 nov. 2011, Date de fin: 31 oct. 2015,
The purpose of the project is to identify genome-based biomarkers for use in clinical practice to individualise treatment of epilepsy, and stratify patients for clinical trials, aiming to avoid chronicity, prevent relapse and reduce adverse drug reactions (ADRs).The need for improved treatments in epilepsy is undoubted. Epilepsy is affects 50,000,000 people of all ages worldwide. Epilepsy is serio ...
Voir le projet
15
Participants partenaires
TERMINÉ
Long-term PHARMacovigilance for Adverse effects in Childhood arthritis focussing on Immune modulatory drugs (PHARMACHILD)
Date du début: 1 avr. 2011, Date de fin: 30 sept. 2014,
Until the age of biotechnology, treatment options for children and adolescents with severe arthritis, inflammatory bowel diseases and other serious diseases with chronic inflammation were limited. Advances in understanding the pathophysiology of the inflammatory responses have led to the development of a new class of medications that are capable of inhibiting selectively the principal mediators of ...
Voir le projet
9
Participants partenaires
TERMINÉ
Therapeutic challenge in Leukodystrophies: Translational and ethical research towards clinical trials (LEUKOTREAT)
Date du début: 1 mars 2010, Date de fin: 31 août 2013,
Leukodystrophies (LDs) are inherited rare neurodegenerative diseases of the white matter and its main component, the myelin, that are affecting predominantly children. Severity of the disease is related to the axonal dysfunction due to myelin deficiency or destruction. Despite the achievement of remarkable advances made in the past decade, there is no current curative therapy. The development of t ...
Voir le projet
25
Participants partenaires
TERMINÉ
Understanding inflammation-associated tumorigenesis for the rational design of novel anti-cancer therapeutic strategies (INFLA-CARE)
Date du début: 1 janv. 2009, Date de fin: 30 juin 2013,
Epidemiological and experimental evidence supports a link between chronic inflammation and cancer and indicates a role for inflammatory cells in the initiation, progression and metastasis of malignancy. The objective of the collaborative integrated project INFLA-CARE is to structure a European collective of scientific and technological excellence in the field of ‘Inflammation & Cancer’ which will ...
Voir le projet
22
Participants partenaires
TERMINÉ
Natural course, pathophysiology, models for early diagnosis, prevention and innovative treatment of TNF Receptor Associated Periodic Syndrome TRAPS with application for all hereditary recurrent fevers (EUROTRAPS)
Date du début: 1 avr. 2008, Date de fin: 30 sept. 2011,
The TNF Receptor Associated Syndrome (TRAPS) is a rare disease of innate immunity, caused by mutations in TNFR1. It is characterised by recurrent bouts of fever and pain and mainly affects patients of European ancestry. The development of renal amyloidosis in up to 20% of cases makes it a potentially fatal disease. Corticosteroids and anti-TNF therapeutics have not been consistently effective in c ...
Voir le projet
9
Participants partenaires
TERMINÉ
European initiative to improve knowledge, treatment and survival of haemophagocytic syndromes in children (CureHLH)
Date du début: 1 juin 2008, Date de fin: 31 mai 2011,
Haemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening inherited immune disorder of early childhood characterised by an uncontrolled immune response. Three disease causing genes have been identified in about half of the patients. Diagnosis is difficult, pathophysiology poorly understood, and treatment unsatisfactory with about 40% of the children dying from treatment failure or t ...
Voir le projet
9
Participants partenaires
TERMINÉ
Innate immunity crosstalk in immunoregulation (INNATE_CROSSTALK)
Date du début: 1 juil. 2008, Date de fin: 30 juin 2009,
"Innate immunity is believed to protect mammalians from most infections. In the majority of cases, the quick responses by innate effector cells clear the infection before adaptive immunity develops. In recent years it has become evident that the early crosstalk between different innate immune cells also has a role in the development of adaptive immunity. In particular, NK-dendritic cell (DC) inter ...
Voir le projet